奥沙利铂联合卡培他滨治疗胃癌术后淋巴转移的近期疗效

Short-term Response of Combination Chemotherapy of Oxaliplatin and Capecitabine in the Treatment for Lymph Node Metastasis in Gastric Cancer Postoperation

[目的]探讨奥沙利铂联合卡培他滨治疗胃癌手术后淋巴转移的近期疗效。[方法]48例胃癌手术后淋巴转移患者采用奥沙利铂联合卡培他滨方案治疗共176个周期。[结果]CR4例,PR28例,NC12例和PD4例,总有效率(CR+PR)为66.7%(32/48)。中位缓解期6.2个月,中位生存期12.3个月,1年生存率为60.5%,临床受益者共44例(90.5%)。毒副反应可耐受,无患者因为毒副反应终止治疗,无相关死亡出现。[结论]奥沙利铂加卡培他滨方案治疗胃癌手术后淋巴转移疗效较好,毒副反应能够耐受,可作为一线方案在胃癌手术后淋巴转移的病人中应用。

[Purpose] To investigate the short-term response of combination chemotherapy of oxaliplatin and eapeeitabine in the treatment for lymph node metastasis in gastric cancer postoperation. [Methods] Forty-eight cases with postoperative lymphnode metastasis were treated with oxaliplatin and capecitabine for 176 cycles. [Results] The overall response rate was 66.7%（32/48）, with CR in 4 cases; NC, 12; and PD, 4. The median disease free survival was 6.2 months, the median survival was 12.3 months and the 1 year survival rate was 60.5%. Forty-four cases （90.5%） benefited from this regimen. The toxicities were tolerable, and none was death or stopped chemotherapy attributed to toxicity. [Conclusions] Combination chemotherapy of oxaliplatin and capecitabine was certainly effective and toxicity tolerable in patients with lymph node metastasis after gastric cancer surgery. The regimen may be used as a first-line chemotherapy in lymph node metastasis after gastric cancer surgery.